
Developing a new class of GI vaccines
Imagine a world where a single vaccine can protect children against both rotavirus and norovirus - the leading cause of severe viral gastroenteritis in kids
At GIVAX, we're making this vision a reality. Using our groundbreaking platform technology, we're developing a new class of GI vaccines that could revolutionize the way we protect against GI pathogens.
About Us
Norovirus is a Severe & Highly Contagious Disease Especially for Children
Highly Disruptive
Norovirus causes severe diarrhea, nausea & vomiting, malaise, muscle pains and headaches
Outbreaks occur frequently in schools, daycares, long-term care facilities, cruise ships & military operations
With a 50% infection probability, it remains one of the most infectious GI pathogens globally¹
High Burden of Disease
Norovirus causes illness in 450 million children & 80 million older adults annually²
Norovirus has replaced rotavirus as the most significant GI viral pathogen in children within high-income countries³
The virus leads to 95,000 deaths annually in children and 80,000 deaths in older adults worldwide²
The global economic burden of norovirus is estimated to be $60 billion annually²
GIVAX is Transforming The Existing Rotavirus Vaccines into a Platform For Safe & Effective GI Vaccines
A Novel Oral Replicating Rotavirus Vector
Established Safety Profile
Pediatric vector based on licensed vaccines; adult vector has demonstrated clinical safety
Drives Activation of Mucosal Immunity
Demonstrated ability to induce de-novo mucosal immunity in the GI tract, key for naive pediatric population
Flexible Platform
Easy to update antigen composition to match circulating strains without changing manufacturing processes
Acting as a Platform for High-Value GI Vaccines
Dual Rotavirus/Norovirus Vaccine for Pediatrics
A combined approach targeting both rotavirus and norovirus for children.Norovirus Vaccine for Adults
Focused on providing protection for adults against norovirus.Potential for Other GI Vaccines
Offers the capability to develop vaccines for other gastrointestinal pathogens, such as Clostridioides difficile (C. Diff).
Latest News
1.13.2025 | Science
Why the ‘Ferrari of viruses’ is surging through the Northern Hemisphere
By Jon Cohen
11.5.2024 | LinkedIn
GIVAX presents at 2024 World Vaccine Congress
11.19.2022 | PubMed
The Challenges & Opportunities of Next-Generation Rotavirus Vaccines: 2022 2nd Generation Rotavirus Vaccine Developers Meeting
By Jessie Chen, Stephanie Grow, Miren Iturriza-Gómara, William P Hausdorff, Alan Fix, Carl D Kirkwood